Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing\n\n\n\n TORONTO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“\n \n Quantum BioPharma\n \n ” or the “\n \n Company\n \n ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that on July 31, 2025 it filed a memorandum of law in opposition to defendants’ CIBC World Markets (“CIBC”) and RBC Dominion Securities (“RBC”) joint motion to dismiss in the United States District Court for the Southern District of New York. This reply can be accessed via the following link:\n \n Memorandum of Law as Filed\n \n .\n \n\n This is Quantum’s response to a memorandum of law that CIBC and RBC filed on June 16, 2025, in support of a joint motion to dismiss the Amended Complaint filed by Quantum BioPharma on May 31\n \n st\n \n , 2025. The amendment complaint filed by Quantum BioPharma allege that CIBC World Markets, RBC Dominion Securities, and others (the “Defendants”) engaged in market manipulation schemes that violated Section 10(b) and Rule 10b-5(a) and (c) and Section 9(a) of the Securities Exchange Act of 1934. This lawsuit alleges that between\n \n 1\n \n\n\n st\n \n\n\n of January 2020\n \n , and\n \n 15\n \n\n\n th\n \n\n\n of August 2024\n \n the Defendants and/or their customers used “spoofing” techniques to manipulate the share price of Quantum BioPharma shares. Quantum is seeking damages of more than\n \n $700 Million USD\n \n .\n \n\n The Company has posted a copy of the memorandum of law in opposition reply to the motion to dismiss filed July 31, 2025, the amended complaint, as well as the original complaint, on its website on the Quantum vs Banks page. A copy of all the filings can be found at\n \n https://www.quantumbiopharma.com/quantum-biopharma-vs-banks\n \n .\n \n\n The law firms Christian Attar and Freedman Normand Friedland LLP have agreed to take and file this case on a contingency basis and, as such, there will be no material financial pressure on the Company to bear the legal costs associated with this case. These law fi...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B